Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL11016417 | 0.91 | CYP2D6 (0.45) | HTR2AHTR2CHTR7CYP11B2CYP2D6 | |
| SCHEMBL1348883 | 0.86 | HTR2A (0.58) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL31489727 | 0.82 | HTR2A (0.55) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL3051979 | 0.82 | HTR2A (0.55) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL29448585 | 0.81 | MEN1 (0.45) | CYP2D6 | |
| SCHEMBL3591892 | 0.81 | RPS6KB1 (0.43) | — | |
| SCHEMBL3587509 | 0.81 | RPS6KB1 (0.43) | — | |
| SCHEMBL16400056 | 0.81 | SLC6A4 (0.53) | CYP2D6 | |
| SCHEMBL3591894 | 0.81 | RPS6KB1 (0.43) | — | |
| SCHEMBL1405679 | 0.81 | KDM4E (0.49) | HTR2AHTR2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103930407-B | Aminopyrimidine derivatives useful as modulators of kinase activity | 默克专利有限公司 | 2019-02-26 | — | — | CN | disclosed |
| EP-3057422-A1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | Janssen Pharmaceutica NV (BE) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057626-A1 | QUINOLINYL MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
| CN-101605783-A | Novel N, N' -2, 4-dianilinopyrimidine derivatives as drugs, pharmaceutical compositions, especially as IKK inhibitors, and preparation thereof | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | CN | disclosed |
| EP-2118092-A1 | NEW N, N'- 2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009056693-A1 | NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008099073-A1 | N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| CN-1547575-A | Novel phenylalkyldiamine and amide analogs | SK��ʽ���� | 2004-11-17 | — | — | CN | disclosed |
| US-4921863-A | Cyclic amine derivatives | EISAI CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| CN-1035823-A | 1, the 4-Disubstituted-piperidnyl compounds | MERRELL DOW PHARMA (US) | 1989-09-27 | — | — | CN | disclosed |
| EP-0325268-A1 | 1,4-Disubstituted-piperidinyl compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| US-4797489-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | AMERICAN HOME PRODUCTS CORP. (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0288563-A1 | CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1988-11-02 | — | — | EP | disclosed |
| EP-0070053-B1 | NOVEL BICYCLIC PYRIMIDIN-5-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-04-16 | — | — | EP | disclosed |
| US-4548938-A | PSYCHOTROPIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-22 | — | — | US | disclosed |
| US-4529727-A | Pyrimido[2,1-b][1,3]-thiazines | JANSSEN PHARMACEUTICAL, N.V. (BE) | 1985-07-16 | — | — | US | disclosed |
| US-4443451-A | PSYCHOTROPIC, ANTIHISTAMINES, ANTISEROTONINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-04-17 | — | — | US | disclosed |
| EP-0070053-A2 | Novel bicyclic pyrimidin-5-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | CHUK, IKBKB, IKBKE | HTR2A 3869/4885HTR2C 4010/4885HTR7 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.